Myriad Genetics 8-K
Leadership change
Brian Donnelly’s separation agreement provides severance and accelerated time-based equity in exchange for a claims release and restrictive covenants.
Filed 2026-10-09 16:16 ET
- 5.02 Officer/director change
- 9.01 Financial Statements and Exhibits
Summary
Separation agreement with former Chief Commercial Officer Brian Donnelly. Donnelly left the role effective 9/16/2026 and employment ended 9/21/2026. The agreement provides severance and equity treatment in exchange for a release of claims and compliance with restrictive covenants; it becomes effective 10/14/2026 if he does not revoke it before then.
Key Figures
- Severance: $1.32M lump sum.
- Time-based equity awards scheduled to vest within two years after the separation date accelerate, with annual installments deemed to vest monthly over that period.
- Performance-based awards remain outstanding; any earned portion scheduled to vest within two years after the separation date may vest if the applicable performance condition is met within that period.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3